256 related articles for article (PubMed ID: 32761371)
1. Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature.
Heck J; Stichtenoth DO; Mettin R; Jöckel J; Bickel C; Krichevsky B
Eur J Clin Pharmacol; 2021 Jan; 77(1):141-144. PubMed ID: 32761371
[No Abstract] [Full Text] [Related]
2. Remdesivir Use in COVID-19 Patients: Cutaneous Adverse Effect or Disease Manifestation?
Pulsipher KJ; Presley CL; Szeto MD; Waller JD; Dellavalle RP
J Drugs Dermatol; 2021 May; 20(5):575. PubMed ID: 33938699
[No Abstract] [Full Text] [Related]
3. Symmetrical drug-related intertriginous and flexural exanthema caused by valacyclovir.
Daito J; Hanada K; Katoh N; Katoh S; Sakamoto K; Asai J; Takenaka H; Kishimoto S
Dermatology; 2009; 218(1):60-2. PubMed ID: 18974630
[TBL] [Abstract][Full Text] [Related]
4. Symmetrical drug related intertriginous and flexural exanthema (SDRIFE) induced by fluconazole: An uncommon side effect of a commonly used drug.
Kumar S; Bhale G; Brar BK
Dermatol Ther; 2019 Nov; 32(6):e13130. PubMed ID: 31659833
[No Abstract] [Full Text] [Related]
5. Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Caused by Etoricoxib.
Caralli ME; Seoane Rodríguez M; Rojas Pérez-Ezquerra P; Pelta Fernández R; De Barrio Fernández M
J Investig Allergol Clin Immunol; 2016; 26(2):128-9. PubMed ID: 27164635
[No Abstract] [Full Text] [Related]
6. A case of fixed drug eruption induced by doxycycline, mimicking a symmetrical drug-related intertriginous and flexural exanthema (SDRIFE).
Favrelière S; Hosteing S; Jazeron JF; Allouchery M; Lafay-Chebassier C; Perault-Pochat MC
Therapie; 2020; 75(5):511-513. PubMed ID: 31761151
[No Abstract] [Full Text] [Related]
7. A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination.
Manaa A; Ziv M; Krausz J; Dodiuk-Gad RP
Dermatol Ther; 2022 Jul; 35(7):e15546. PubMed ID: 35485220
[No Abstract] [Full Text] [Related]
8. Rare case of itraconazole induced SDRIFE (symmetrical drug-related intertriginous and flexural exanthema).
Koschitzki K; Karrer S; Berneburg M; Niebel D; Drexler K
J Dtsch Dermatol Ges; 2024 Jun; 22(6):833-836. PubMed ID: 38567643
[No Abstract] [Full Text] [Related]
9. Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man.
Day LB; Abdel-Qadir H; Fralick M
CMAJ; 2021 Apr; 193(17):E612-E615. PubMed ID: 33903133
[No Abstract] [Full Text] [Related]
10. Docetaxel-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) confirmed by skin testing.
Hampel A; Kinaciyan T
Contact Dermatitis; 2024 May; 90(5):525-527. PubMed ID: 38263696
[No Abstract] [Full Text] [Related]
11. Safety profile of the antiviral drug remdesivir: An update.
Fan Q; Zhang B; Ma J; Zhang S
Biomed Pharmacother; 2020 Oct; 130():110532. PubMed ID: 32707440
[No Abstract] [Full Text] [Related]
12. Lenalidomide-induced symmetrical drug-related intertriginous and flexural exanthema.
Patel RT; Quan EY; Eikenberg JD; Grider DJ; Phillips MA
Dermatol Online J; 2023 Aug; 29(4):. PubMed ID: 37921816
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.
Med Lett Drugs Ther; 2022 Feb; 64(1644):31-32. PubMed ID: 35171898
[No Abstract] [Full Text] [Related]
14. Remdesivir for patients with COVID-19.
Wu PE; Morris AM
CMAJ; 2021 Jan; 193(4):E125. PubMed ID: 33408097
[No Abstract] [Full Text] [Related]
15. Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study.
Attena E; Albani S; Maraolo AE; Mollica M; De Rosa A; Pisapia R; Fiorentino G; Parrella R; Severino S; Russo V
Circ Arrhythm Electrophysiol; 2021 Jul; 14(7):e009811. PubMed ID: 34182791
[No Abstract] [Full Text] [Related]
16. Remdesivir for the treatment of COVID-19 in pregnancy.
Lampejo T
J Med Virol; 2021 Jul; 93(7):4114-4119. PubMed ID: 33788273
[No Abstract] [Full Text] [Related]
17. Symmetrical drug-related intertriginous and flexural exanthema due to ranitidine.
Binitha MP; Sasidharanpillai S; John R; Sherjeena PV
Indian J Pharmacol; 2014; 46(5):551-2. PubMed ID: 25298589
[TBL] [Abstract][Full Text] [Related]
18. Reply to "A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination" by Manaa et al.
Camela E; Scalvenzi M; Megna M; Potestio L; Guerrasio G; Fornaro L; Fabbrocini G; Costa C
Dermatol Ther; 2022 Dec; 35(12):e15881. PubMed ID: 36181410
[No Abstract] [Full Text] [Related]
19. Symmetrical drug-related intertriginous and flexural exanthema with high-risk systemic features: a unique clinical phenotype in hospitalized patients.
Kirven RM; Fisher K; Kaffenberger BH; Chung CG; Korman AM
Arch Dermatol Res; 2024 May; 316(6):279. PubMed ID: 38796524
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
Lewis W; Forrestel A; Baumrin E
Cutis; 2023 Jan; 111(1):18-21. PubMed ID: 36947773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
